Facebook
Twitter
LinkedIn

Media Center

FAST, Fellows and CARB-X Update July 2020
Facebook
Twitter
LinkedIn

FAST & Fellows 

Shasqi (FAST Spring 2016), a leader in chemistry based locally-activated cancer drugs, has presented data showing that the company’s lead candidate SQ3370 produced robust anti-tumor responses both at the target site and at distal lesions in a preclinical cancer model. This new therapeutic modality can precisely control the duration of exposure and magnitude of activated drugs at a specific area in the body. This allows the exploration of therapeutic benefits of a drug that had been previously limited by existing routes of administration in the clinic (oral, intravenous, direct injection or controlled release).  Read more…

Paragon Genomics (FAST Spring 2016), a leader in amplicon-based target enrichment solutions for next-generation sequencing (NGS) and precision medicine, today reported that its scientists have developed methods allowing for a multi-fold increase in the throughput of its CleanPlex SARS-CoV-2 NGS Panel for COVID-19 research, testing and surveillance.

This increased capacity, along with the CleanPlex Panel’s fast time to results, efficient workflow, and affordable cost, could help achieve the high-volume testing that will be needed to facilitate the safe re-opening of institutions such as schools and workplaces that have had to close or restrict their operations as a result of the pandemic.   Read more…

Raydiant Oximetry (FAST Spring 2017) was awarded a $203K Phase 1 Small Business Innovation Research (SBIR) SBIR grant from the NIH on July 1, 2020. This is their third SBIR grant to date. They also received a favorable summary for a Phase 2 SBIR from the NSF, which could lead to an additional award of $1 million dollars later this year.

Pendulum Therapeutics (FAST Spring 2014), a cutting-edge microbiome company dedicated to making people healthier through microbiome-targeted solutions, announced the launch of Pendulum Glucose Control, the first and only medical probiotic clinically shown to lower A1C and blood sugar spikes. Pendulum Glucose Control is designed specifically for the dietary management of type 2 diabetes, a condition affecting nearly 30 million Americans. Pendulum Glucose Control is a medical food to be used under supervision of a physician.    Read more…

CARB-X 

CARB-X is awarding Vaxdyn, based in Seville, Spain, up to US$892,000, plus an additional $6.36 million if certain project milestones are met, to develop a new vaccine to prevent life-threatening drug-resistant infections, including pneumonia. Vaxdyn is the first Spanish biotech to be funded by CARB-X. Read more…

CARB-X is awarding up to US$3.83 million to the University of Queensland’s Institute for Molecular Bioscience, Brisbane, Australia, to develop a new class of antibiotics to treat serious drug-resistant bacterial infections. The goal is to develop a safer antibiotic to replace last-resort polymyxin class antibiotics, such as colistin.  Read more…

CARB-X announced today it is awarding US$4.6M to Amicrobe Inc. to expand development of its bioengineered Amicidin-β synthetic protein designed to kill bacteria and cleanse tissues. The new funding will help accelerate IND-enabling work on Amicidin-β Solution, which targets treatment of serious surgical and traumatic wound infections and will also support prototyping of a new product for prevention of infection in low- and middle-income countries (LMIC’s).  Read more…